TY - JOUR
T1 - Robotic versus Open Pyeloplasty: Perioperative and Functional Outcomes
AU - Moretto, Stefano
AU - Gandi, Carlo
AU - Bientinesi, Riccardo
AU - Totaro, Angelo
AU - Marino, Filippo
AU - Gavi, Filippo
AU - Russo, Andrea
AU - Aceto, Paola
AU - Pierconti, Francesco
AU - Bassi, Pierfrancesco
AU - Sacco, Emilio
PY - 2023
Y1 - 2023
N2 - We designed a retrospective study to assess the surgical and economic outcomes of robot-assisted laparoscopic pyeloplasty (RALP) compared with open pyeloplasty (OP), including consecutive patients suffering from ureteropelvic junction obstruction and operated on from January 2012 to January 2022 at a single center. Preoperative, intraoperative, and postoperative outcomes, including costs, were comparatively analyzed. The primary outcome was 3-month success, defined as symptom resolution and no obstruction upon diuretic renal scintigraphy. Overall, 91 patients were included (48 OP and 43 RALP). The success rate at 3 months was 93.0% and 83.3% in the RALP and OP group, respectively (p = 0.178), and the results remained stable at the last follow-up (35.4 +/- 22.8 months and 56.0 +/- 28.1 months, respectively). Intraoperative blood loss (p < 0.001), need for postoperative analgesics (p = 0.019) and antibiotics (p = 0.004), and early postoperative complication rate (p = 0.009) were significantly lower in the RALP group. None of the assessed variables were a predictor for failure. The mean total direct cost per surgical procedure and related hospital stay was 2373 euro higher in the RALP group. RALP is an effective and safe treatment for ureteropelvic junction obstruction; however, further studies are needed to evaluate the cost-effectiveness of RALP, accounting for indirect costs and cost-saving with new surgical platforms.
AB - We designed a retrospective study to assess the surgical and economic outcomes of robot-assisted laparoscopic pyeloplasty (RALP) compared with open pyeloplasty (OP), including consecutive patients suffering from ureteropelvic junction obstruction and operated on from January 2012 to January 2022 at a single center. Preoperative, intraoperative, and postoperative outcomes, including costs, were comparatively analyzed. The primary outcome was 3-month success, defined as symptom resolution and no obstruction upon diuretic renal scintigraphy. Overall, 91 patients were included (48 OP and 43 RALP). The success rate at 3 months was 93.0% and 83.3% in the RALP and OP group, respectively (p = 0.178), and the results remained stable at the last follow-up (35.4 +/- 22.8 months and 56.0 +/- 28.1 months, respectively). Intraoperative blood loss (p < 0.001), need for postoperative analgesics (p = 0.019) and antibiotics (p = 0.004), and early postoperative complication rate (p = 0.009) were significantly lower in the RALP group. None of the assessed variables were a predictor for failure. The mean total direct cost per surgical procedure and related hospital stay was 2373 euro higher in the RALP group. RALP is an effective and safe treatment for ureteropelvic junction obstruction; however, further studies are needed to evaluate the cost-effectiveness of RALP, accounting for indirect costs and cost-saving with new surgical platforms.
KW - dismembered pyeloplasty
KW - open pyeloplasty
KW - robot-assisted laparoscopic pyeloplasty
KW - ureteropelvic junction obstruction
KW - dismembered pyeloplasty
KW - open pyeloplasty
KW - robot-assisted laparoscopic pyeloplasty
KW - ureteropelvic junction obstruction
UR - http://hdl.handle.net/10807/243737
U2 - 10.3390/jcm12072538
DO - 10.3390/jcm12072538
M3 - Article
SN - 2077-0383
VL - 12
SP - 2538-N/A
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
ER -